Prospective, explorative trial for the detection of circulating cell-free tumor DNA in the plasma of patients with gastrointestinal stromal tumors (GIST) harboring activating mutations of CKIT or PDGFRA pre/post surgery or pre/under treatment with a tyrosine kinase inhibitor or progressive disease irrespective of current or planned treatment. An open-label, non-randomized, multicenter phase IIIb clinical trial.

Trial Profile

Prospective, explorative trial for the detection of circulating cell-free tumor DNA in the plasma of patients with gastrointestinal stromal tumors (GIST) harboring activating mutations of CKIT or PDGFRA pre/post surgery or pre/under treatment with a tyrosine kinase inhibitor or progressive disease irrespective of current or planned treatment. An open-label, non-randomized, multicenter phase IIIb clinical trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2015

At a glance

  • Drugs Imatinib (Primary) ; Sunitinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms CF DNA GIST
  • Most Recent Events

    • 19 Dec 2015 Status changed from recruiting to completed, according to European Clinical Trials Database record.
    • 01 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top